Apellis' eye disease drug gets safety label update for rare inflammation side effect
The FDA and Apellis Pharmaceuticals have updated the label for Syfovre — an injection for late-stage wet age-related macular degeneration — to address the potential risk of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
